Galderma's constant-currency sales grew 26% in the third quarter, driven by strong volumes and positive mix effects. Results beat company-compiled consensus estimates by 6%, driving a 6% intraday increase in the stock price on Oct. 22.
Galderma’s sizable innovation pipeline should translate into accelerated revenue growth and EBITDA margin accretion over the midterm.
The agreement with Ipsen for the current neuromodulator portfolio features stepped royalties that have been weighing on margins and may limit the company in pursuing volume market share growth.
|
Metric
|
GALD
|
OR
|
BEI
|
|---|---|---|---|
Price/Earnings (Normalized) | 60.25 | 34.52 | 13.75 |
Price/Book Value | 6.50 | 6.77 | 1.95 |
Price/Sales | 9.27 | 5.07 | 1.83 |
Price/Cash Flow | 45.95 | 26.29 | 14.94 |
|
Metric
|
GALD
|
OR
|
BEI
|
|---|---|---|---|
Quick Ratio | 0.93 | 0.58 | 1.50 |
Current Ratio | 1.24 | 0.97 | 2.00 |
Interest Coverage | 6.84 | 19.89 | 42.97 |
|
Metric
|
GALD
|
OR
|
BEI
|
|---|---|---|---|
Return on Assets (Normalized) | 7.31% | 11.46% | 7.60% |
Return on Equity (Normalized) | 12.07% | 20.96% | 11.37% |
Return on Invested Capital (Normalized) | 10.17% | 15.09% | 10.80% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|>R?<<B>g | LOCK|pl%&G | $70B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|!&Cb%LR> | LOCK|cM<c% | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|&!wljN | LOCK|wpZ | $44B | |||
| Zoetis Inc Class A
ZTS
| LOCK|G?@<S$Xm | LOCK|y^f | $32B | |||
| Viatris Inc
VTRS
| LOCK|M&N$Nw | LOCK|ff | $22B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|$c<%&<b | LOCK|!f< | $11B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|T^ | LOCK|!<d | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|@>>$Z<V | LOCK|K$# | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|<Sy>S$ | LOCK|<>^& | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|sz&@M#S | LOCK|M? | $2B |
United States